May 14 2021
IMMUNO-ONCOLOGY, TARGETING CD20
INOVOTION has a new in vivo assay for Anti-CD20 therapies and B-Cell targeting.
Our R&D team has recently set up and validated a highly specific new assay based on Rituximab and
Daudi cells on chicken embryos.
This changes the landscape by opening a large range of possibilities for rapidly evaluating anti-CD20
therapies and combinations.
Let’s talk about your projects to see how this new assay will further your R&D !!
Feel free to also contact us directly via our contact page.
Nov 13
2024
Come see us at the EPAA
Come see us at the EPAA (European Partnership for Alternative Approaches to Animal Testing) 2024 Annual Conference INOVOTION will be at the European Partnership for Alternative Approaches to Animal Testing (EPAA) Annual Conference 2024, November […]
Nov 6-10
2024
Come see us at the SITC
Come see us at the SITC (Society for Immunotherapy of Cancer) 39th Annual Meeting, November 6-10, 2024, in Houston! SITC 2024 is the world’s leading showcase of advances in cancer immunology and immunotherapy, bringing together […]
Nov 4-6
2024
Come see us at Bio-Europe Fall
